New multiple myeloma therapy shows promise in preclinical study

New multiple myeloma therapy shows promise in preclinical study

Press releases may be edited for formatting or style | August 07, 2020 Molecular Imaging
Reston, VA—A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

Multiple myeloma is a plasma cell cancer that occurs in bone marrow. It is the second most common type of blood cancer, with more than 32,000 new cases projected in 2020, according to the American Cancer Society. Despite new treatments and protocols, the prognosis of multiple myeloma patients remains poor, as remission is often followed by relapse. Innovative therapies with a distinct mechanism of action are therefore needed.

“Targeted radioimmunotherapy using antibodies against proteins expressed at the cell membrane on tumoral cells has already shown efficacy with beta-emitters, but with severe side effects,” said Isabelle Quelven-Bertin, PharmD, radiopharmacist at Limoges University Hospital in Limoges, France. “Using alpha particles is very attractive because their much shorter path-length reduces unwanted radiation exposure on normal tissues, thereby reducing side effects. As such, we investigated the potential of the α-radioimmunotherapy 212Pb-anti-CD38 in the treatment of multiple myeloma.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

In the study, researchers developed human myeloma cell lines, which were analyzed for cell proliferation after incubation with various concentrations of 212Pb monoclonal antibodies. Mice received subcutaneous grafts of human myeloma cell lines and were injected with 212Pb-anti-CD38, 212Pb-anti-mCD38 (mice-specific) or 212Pb-isotypic control. Biodistribution, toxicity and dose-range-finding studies were performed, as well as radioimmunotherapy experiments that measured tumor volume and overall survival.

The human myeloma cell line saw a significant inhibition of cell proliferation three days after incubation with 212Pb-anti-CD38. Likewise, the mouse model showed marked inhibition of cell proliferation for mice treated with 212Pb-anti-CD38, with a median survival of 55 days; mice that received the isotypic control had a median survival of 11 days. Biodistribution studies showed a specific tumoral accumulation of 212Pb-anti-CD38, and toxicity experiments with 212Pb-anti-mCD38 established a toxic activity of 277.5 kBq.

You Must Be Logged In To Post A Comment